A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

NCT04732286 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped The study was completed as pre-specified in the protocol. Study was terminated only for participants who were in the study even after 24 months of follow-up as specified in the protocol.

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab

Sponsor

Hoffmann-La Roche